World Health Organization site
Skip Navigation Links

Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 12 December 2020
Main ID:  NCT02318537
Date of registration: 12/12/2014
Prospective Registration: Yes
Primary sponsor: INSYS Therapeutics Inc
Public title: Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome
Scientific title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Interventional Study to Assess the Safety and Efficacy of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Subjects With Inadequately Controlled Lennox-Gastaut Syndrome
Date of first enrolment: December 30, 2017
Target sample size: 0
Recruitment status: Withdrawn
URL:  https://clinicaltrials.gov/show/NCT02318537
Study type:  Interventional
Study design:  Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Participant, Care Provider, Investigator).  
Phase:  Phase 3
Countries of recruitment
Contacts
Name:     Neha Parikh
Address: 
Telephone:
Email:
Affiliation:  INSYS Therapeutics Inc
Key inclusion & exclusion criteria

Inclusion Criteria:

- Meets protocol-specified criteria for qualification and contraception, including
clinical diagnosis of refractory LGS and onset of seizures according to
protocol-specified criteria

- Is able to speak and understand the language in which the study is being conducted, is
able to understand the procedures and study requirements and has voluntarily signed
and dated an informed consent form approved by the Institutional Review Board before
the conduct of any study procedure

- In the opinion of the Investigator, the participants and parent(s)/caregiver(s) are
willing and able to comply with the study procedures and visit schedules, including
venipuncture, twice daily dosing, accurate diaries, and the Follow-up Visits (if
applicable).

Exclusion Criteria:

- Medical history is outside protocol-specified parameters

- Clinically significant history of allergic reactions or significant sensitivities to
cannabinoids or to any of the other ingredients in the study drug

- Inadequate supervision by parents or guardians

- History or current use of dietary supplements, drugs or over-the counter medications
outside protocol-specified parameters

- Signs, symptoms or history of any condition that, per protocol or in the opinion of
the investigator, might compromise: 1) the safety or well-being of the participant or
study staff; 2) the safety or well-being of the participant's offspring (such as
through pregnancy or breast-feeding); 3) the analysis of results



Age minimum: 2 Years
Age maximum: 30 Years
Gender: All
Health Condition(s) or Problem(s) studied
Lennox-Gastaut Syndrome
Intervention(s)
Drug: Cannabidiol Oral Solution
Drug: Placebo Solution
Primary Outcome(s)
Percent change from baseline in the frequency of motor seizures involving the trunk or extremities [tonic, atonic, generalized tonic-clonic (GTC), focal seizures with motor components (FSMC)] [Time Frame: Data point for observation period to data point for treatment period Weeks 9 through 12]
Secondary Outcome(s)
Change from baseline in Investigator CGI-I [Time Frame: Data point for observation period to data point for treatment period Weeks 9 through 12]
Change from baseline in Investigator CGI-S [Time Frame: Data point for observation period to data point for treatment period Weeks 9 through 12]
Change from baseline in parent(s)/caregiver(s) Clinical Global Impressions of Improvement (CGI-I) [Time Frame: Data point for observation period to data point for treatment period Weeks 9 through 12]
Change from baseline in parent(s)/caregiver(s) Clinical Global Impressions of Severity (CGI-S) [Time Frame: Data point for observation period to data point for treatment period Weeks 9 through 12]
Percent change from baseline in frequency of all seizure activity independent of seizure type [Time Frame: Data point for observation period to data point for treatment period Weeks 9 through 12]
Percent change from baseline in severity of motor seizures involving the trunk or extremities (tonic, clonic, GTC, FSMC) [Time Frame: Data point for observation period to data point for treatment period Weeks 9 through 12]
Percent change from baseline in the duration of all seizure activity independent of seizure type [Time Frame: Data point for observation period to data point for treatment period Weeks 9 through 12]
Percent change from baseline in the severity of all seizure activity independent of seizure type [Time Frame: Data point for observation period to data point for treatment period Weeks 9 through 12]
Secondary ID(s)
INS011-14-024
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history